Ezra Cohen, MD, FRCPSC, FASCO - Mapping Progress With Immune Checkpoint Inhibitors in Head and Neck Cancer: Expert Views on Immunotherapy as a Component of Multimodal Care

1:10:47
 
Share
 

Manage episode 238390321 series 9912
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Go online to PeerView.com/XFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Already a cornerstone of care for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), immune checkpoint inhibitors are being explored in earlier treatment settings and in combination with other pillars of SCCHN care (such as surgery and radiotherapy). In this MasterClass activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 ASCO Annual Meeting, experts in head and neck (HNC) explore the evidence that is redefining the role of immunotherapy in HNC and offer insight on applications of new evidence on immunotherapy in HNC, as well as its future as a part of multimodal treatment plans. This activity also features a dedicated “Tumor Board” session designed to provide useful guidance on integrating checkpoint inhibitors into care—from the selection of upfront immunotherapy to the role of clinical trials as options for patients eligible for immune treatment. Upon completion of this activity, participants will be able to: Summarize evidence on the use of immune checkpoint inhibitors as single agents or in combination with other strategies in recurrent/metastatic, locally advanced, or resectable squamous cell carcinoma of the head and neck, Integrate immune checkpoint inhibitors into the treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck, including as upfront treatment or after progression on platinum chemotherapy, Identify patients with head and neck cancer who are eligible to receive immunotherapy as part of multimodal care across the disease spectrum, including in the context of a clinical trial, Manage immune-related adverse events in patients with squamous cell carcinoma of the head and neck receiving immunotherapy as single agents or in combination with other treatment modalities.

276 episodes available. A new episode about every 3 days averaging 58 mins duration .